Results 161 to 170 of about 64,954 (254)

A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB–IIIB Lung Squamous Cell Carcinoma

MedComm, Volume 7, Issue 7, July 2026.
This phase II trial suggests the potential of perioperative camrelizumab plus neoadjuvant chemotherapy in patients with resectable stage IIB‐IIIB lung squamous cell carcinoma. The major pathological response rate (primary endpoint) was 60.0%, and the pathological complete response (pCR) rate was 44.4%.
Mingming Hu, Shuku Liu, Yi Han, Feng Wang, Yang Liu, Baohua Lu, Hongxia Li, Yuan Gao, Ying Wang, Wei Yang, Kang Shi, Bo Xiao, Qunhui Wang, Juan Du, Haifeng Lin, Xiaomi Li, Chong Wang, Tongmei Zhang   +17 more
wiley   +1 more source

Chemical‐Assembled Macrophage‐Engaging Glypican‐3 × Signal Regulatory Protein‐α (SIRP‐α) Bispecific Antibody for Immunotherapy Against Liver Cancer

MedComm, Volume 7, Issue 7, July 2026.
We developed a novel chemical strategy to generate a glypican‐3 × SIRP‐α bispecific antibody that simultaneously blocks the CD47 “don't eat me” signal, engages macrophages to target liver cancer cells for enhanced phagocytosis, and antigen presentation. This novel combination of targets demonstrates remarkable efficacy in vitro and in vivo.
Bo Tang, Wing Hei Leung, Chihao Shao, Dongfang Li, Kwai Man Lau, Macro K. H. Lui, Jingyi Liu, Jacky C. H. Chu, Clare S. W. Yan, Chi‐Ming Che, Xuechen Li, Wing‐Tak Wong, Larry Ming Cheung Chow, Terence K. W. Lee, Clarence T. T. Wong   +14 more
wiley   +1 more source

The SIRP family: from structural diversity and signaling mechanisms to implications in immune-related disease targeted therapeutics. [PDF]

Front Immunol
Jin Y, Huang Q, Song J, Abideen ZU, Tan R, Xu S, Chen M.   +6 more
europepmc   +1 more source

The Dual Roles of Regulatory B Cells in Infection, Cancer, and Immunity

MedComm, Volume 7, Issue 7, July 2026.
Regulatory B cells maintain immune homeostasis via suppressive cytokines and surface molecules like PD‐L1. While beneficially suppressing autoimmunity and promoting transplant tolerance, these identical mechanisms detrimentally attenuate antipathogen and antitumor immune responses.
Anni Feng, Qilong Li, Ning Jiang, Qijun Chen   +3 more
wiley   +1 more source

Wnt Signaling Downregulation Mediates T Cell Apoptosis Following OKT3-Induced T Cell Activation in Preclinical Models. [PDF]

FASEB J
Choi M, Park D, Lee DH, Choi CH, Jo M, Jeong SY, Lim SY, Park D, Moon KS.   +8 more
europepmc   +1 more source

EGFR‐Targeting IgG1 Antibody Enhances NK Cell‐Mediated Tumor Killing in KRAS‐Mutant Pancreatic Cancer

MedComm, Volume 7, Issue 7, July 2026.
In KRAS‐mutant pancreatic cancer, persistent downstream signaling can limit the efficacy of EGFR‐targeting mAbs. However, the addition of NK cells enables nimotuzumab to effectively direct a potent antitumor response via antibody‐dependent cellular cytotoxicity (ADCC), overcoming this resistance mechanism.
Ruoxi Xiao, Xiaoxiao Li, Ping Li, Junjin Wang, Xiaoyuan Sun, Chenyang Zhao, Zimin Liu, Ruining Gong, Minghan Ren, Ke Lei, He Ren   +10 more
wiley   +1 more source

Candidozyma auris-infected Galleria mellonella larvae: the effect of the humanized monoclonal antibody Dia-T51 and its synergy with amphotericin B. [PDF]

NPJ Antimicrob Resist
Vanzolini T, Fiori V, Magnani M.
europepmc   +1 more source

Model‐Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer

Clinical and Translational Science, Volume 19, Issue 7, July 2026.
ABSTRACT Although tislelizumab is approved across multiple malignancies and dosing schedules, intravenous administration imposes logistical burdens. A subcutaneous formulation may improve convenience and reduce resource demands if comparable exposure is achieved. This study evaluated the pharmacokinetics, bioavailability, and injection‐site performance
Xiangyu Liu, Ye Guan, Yixi Liu, Tian Yu, Ramil Abdrashitov, Ziru Niu, Xiao Lin, Xiaohan Ye, Yutong Wang, Srikumar Sahasranaman, William D. Hanley, Nageshwar Budha   +11 more
wiley   +1 more source

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity. [PDF]

iScience
Kratochvil S, Kullmann M, Gruell H, Sayettat S, Tsai CH, Vukovic N, Janaitis C, Lindemann C, Praßl S, Stumpf R, Knüfer J, Tolksdorf F, Şahin U, Nelke J, Malz A, Schommers P, Bhebhe S, Mkhize N, Moore P, Seaman MS, Klein F, Le Douce V.   +21 more
europepmc   +1 more source